Computational Approaches for Translational Oncology: Concepts and Patents.
暂无分享,去创建一个
[1] D. K. Arrell,et al. Network Systems Biology for Drug Discovery , 2010, Clinical pharmacology and therapeutics.
[2] R. Larsson,et al. Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs , 1995, Anti-cancer drugs.
[3] R Simon,et al. Bayesian Design and Analysis of Active Control Clinical Trials , 1999, Biometrics.
[4] Vered Rom-Kedar,et al. Novel Strategies for Granulocyte Colony-Stimulating Factor Treatment of Severe Prolonged Neutropenia Suggested by Mathematical Modeling , 2008, Clinical Cancer Research.
[5] I. Bleiweiss,et al. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer , 2002, Anti-cancer drugs.
[6] Ivar Østby,et al. A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation , 2003, Journal of mathematical biology.
[7] L. D. Pillis,et al. A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth , 2005 .
[8] P. Carmeliet,et al. SnapShot: Tumor Angiogenesis , 2012, Cell.
[9] Janet Woodcock,et al. The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.
[10] Dominique Barbolosi,et al. Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model , 2000, Comput. Biomed. Res..
[11] Quaid Morris,et al. Fast integration of heterogeneous data sources for predicting gene function with limited annotation , 2010, Bioinform..
[12] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[13] P Hogeweg,et al. Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. , 1985, Journal of immunology.
[14] Magda El-Shenawee,et al. Computational Model of Ductal Carcinoma In Situ: The Effects of Contact Inhibition on Pattern Formation , 2009, IEEE Transactions on Biomedical Engineering.
[15] Vittorio Cristini,et al. Predictions of tumour morphological stability and evaluation against experimental observations , 2011, Journal of The Royal Society Interface.
[16] D. Lauffenburger,et al. Applying computational modeling to drug discovery and development. , 2006, Drug discovery today.
[17] Z Agur,et al. Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. , 1991, Experimental hematology.
[18] F. Pappalardo,et al. In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.
[19] V. Brusic,et al. Mathematical modeling for novel cancer drug discovery and development , 2014, Expert opinion on drug discovery.
[20] Hryniuk Wm. Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.
[21] Pornpimol Charoentong,et al. Mathematical models for translational and clinical oncology , 2013, Journal of Clinical Bioinformatics.
[22] Fabrício F. Costa. Big data in biomedicine. , 2014, Drug discovery today.
[23] Markus Scholz,et al. A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. , 2004, Blood.
[24] David S Wishart,et al. Computational systems biology in drug discovery and development: methods and applications. , 2007, Drug discovery today.
[25] Philip Hahnfeldt,et al. Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy. , 2012, Cancer research.
[26] L. Preziosi,et al. A Hybrid Model Describing Different Morphologies of Tumor Invasion Fronts , 2012 .
[27] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[28] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Peter L. Bonate,et al. Pharmacokinetic-Pharmacodynamic Modeling And Simulation , 2005 .
[30] B. Chabner,et al. Potential roles for preclinical pharmacology in phase I clinical trials. , 1986, Cancer treatment reports.
[31] A. Anderson,et al. A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion , 2005 .
[32] Zhihui Wang,et al. Mathematical modeling in cancer drug discovery. , 2014, Drug discovery today.
[34] Massimo Bernaschi,et al. Computational modeling of the immune response to tumor antigens , 2005 .
[35] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[36] L. Preziosi,et al. A multiscale hybrid approach for vasculogenesis and related potential blocking therapies. , 2011, Progress in Biophysics and Molecular Biology.
[37] Dong Seok Kim. Cancer vaccines in the immunotherapy era: Rational approach , 2013, Human vaccines & immunotherapeutics.
[38] R. Jain,et al. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.
[39] Winston A Hide,et al. Big data: The future of biocuration , 2008, Nature.
[40] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[41] M. Christian,et al. Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Karin M. Verspoor,et al. Combining heterogeneous data sources for accurate functional annotation of proteins , 2013, BMC Bioinformatics.
[43] H E Wichmann,et al. Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis. , 1993, Experimental hematology.
[44] Zvia Agur,et al. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. , 2008, Cancer research.
[45] A. Rossi,et al. Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature. , 2000, Anticancer research.
[46] Alissa M. Weaver,et al. Mathematical modeling of cancer: the future of prognosis and treatment. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[47] L Preziosi,et al. A review of mathematical models for the formation of vascular networks. , 2013, Journal of theoretical biology.
[48] Z. Agur,et al. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. , 2005, Journal of theoretical biology.
[49] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[50] Frank Pokrop. Development of FDA-Regulated Medical Products , 2005 .
[51] S Madani,et al. Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice , 2010, Clinical pharmacology and therapeutics.
[52] R Norel,et al. A model for the adjustment of the mitotic clock by cyclin and MPF levels. , 1991, Science.
[53] Vessela Kristensen,et al. Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy , 2007, BMC Cancer.
[54] D L S McElwain,et al. A history of the study of solid tumour growth: The contribution of mathematical modelling , 2004, Bulletin of mathematical biology.
[55] NOVEL DISEASE TREATMENT BY PREDICTING DRUG ASSOCATION , 2017 .
[56] Krishnendu Chatterjee,et al. Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.